Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of parkinsonism (idiopathic PD, multiple systems atrophy, Lewy body dementia)~* RBD frequency of at least once per week based on the RBD screening clinical questionnaire~* PSG evidence of RBD~* Presence of bed partner/caregiver who sleeps in the same room as PD patient~Exclusion Criteria:~* Known hypersensitivity to ramelteon or related compounds, including melatonin and melatonin-related compounds.~* Use of hypnotics or other sedatives within a month prior to the study initiation~* Presence of active psychosis~* Use of neuroleptics, except for the atypical neuroleptics - specifically quetiapine (the dose should not exceed 50mg/day)~* Use of antidepressants unless the patient has been on a stable dose for at least three months~* Use of Venlafaxine (Effexor®)~* Presence of cognitive impairment, defined as the Mini Mental Status Examination (MMSE) score \<24~* Presence of depression defined as the Beck Depression Inventory (BDI) score \>14~* Significant sleep disordered breathing (defined as an apnea-hypopnea index\>15 events/hr of sleep on screening PSG), significant periodic limb movement disorder (defined as a PLM index\>10 events/hr of sleep with awakening on screening PSG)~* Travel through two time zones within a month prior to the study initiation

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Ramelteon (TAK-375) 8mg tablets
- 2 (Type: PLACEBO_COMPARATOR): Placebo 8 mg tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).